|
|---|
click on the picture above
to interact |
 |
C18 H21 N3 O3 S |
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It was developed by Eisai Co. and is marketed by Janssen-Cilag as rabeprazole sodium under the brand names Aciphex and Pariet.
Rabeprazole is a prodrug (metabolized by the cytochrome P450 (or CYP450)) - in the acid environment of the parietal cells it turns into active sulphenamide form associated with cysteine of H+, K+ATPase (proton pump). Rabeprazole inhibits (partly reversibly) H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
Rabeprazole has anti Helicobacter pylori activity (MIC 4-16 mg/ml) and shows synergistic activity with some antibiotics. Rabeprazole has been demonstrated to be effective in patients with pathological hypersecretory activity (incl. Zollinger-Ellison Syndrome).
Formal Chemical Name (IUPAC)
2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzo[d]imidazole
References
http://en.wikipedia.org/wiki/Rabeprazole
Update by Karl Harrison
(Molecule of the Month for
April 2008
)